Clinical Trial Results:
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
|
Summary
|
|
EudraCT number |
2009-013126-16 |
Trial protocol |
GB FR ES IT |
Global end of trial date |
08 Apr 2026
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Oct 2026
|
First version publication date |
18 Oct 2026
|
Other versions |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
|
Trial identification
|
|||
Sponsor protocol code |
TMC125-TIDP35-C239
|
||
|
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00980538 | ||
WHO universal trial number (UTN) |
- | ||
|
Sponsors
|
|||
Sponsor organisation name |
Janssen-Cilag International NV
|
||
Sponsor organisation address |
Turnhoutseweg 30, Beerse, Belgium, B-2340
|
||
Public contact |
Clinical Registry Group, Janssen-Cilag International N.V., ClinicalTrialsEU@its.jnj.com
|
||
Scientific contact |
Clinical Registry Group, Janssen-Cilag International N.V., ClinicalTrialsEU@its.jnj.com
|
||
|
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
|
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
08 Apr 2026
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
08 Apr 2026
|
||
Was the trial ended prematurely? |
No
|
||
|
General information about the trial
|
|||
Main objective of the trial |
The main objective of the trial was to continue the provision of Etravirine (ETR) for adult and pediatric subjects who previously received ETR in a clinical study sponsored by Janssen Research & Development (JRD), and who continued to benefit from the use of ETR, in countries where at the time parent trial closed, ETR was not commercially available for the subject’s indication, was not reimbursed, could not be accessed through another source (for example, access program or government program), or where the subject was not eligible for ongoing studies/programs with ETR. Trial was closed when last subject was switched to commercial available ETR or to other locally available Human Immunodeficiency Virus (HIV) treatment.
|
||
Protection of trial subjects |
This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and applicable regulatory requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
09 Dec 2009
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
|
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 11
|
||
Country: Number of subjects enrolled |
Brazil: 8
|
||
Country: Number of subjects enrolled |
Canada: 1
|
||
Country: Number of subjects enrolled |
Spain: 7
|
||
Country: Number of subjects enrolled |
France: 3
|
||
Country: Number of subjects enrolled |
Italy: 6
|
||
Country: Number of subjects enrolled |
Panama: 4
|
||
Country: Number of subjects enrolled |
Romania: 1
|
||
Country: Number of subjects enrolled |
Thailand: 12
|
||
Country: Number of subjects enrolled |
United States: 5
|
||
Country: Number of subjects enrolled |
South Africa: 122
|
||
Worldwide total number of subjects |
180
|
||
EEA total number of subjects |
17
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
27
|
||
Adolescents (12-17 years) |
44
|
||
Adults (18-64 years) |
106
|
||
From 65 to 84 years |
3
|
||
85 years and over |
0
|
||
|
|||||||
|
Recruitment
|
|||||||
Recruitment details |
- | ||||||
|
Pre-assignment
|
|||||||
Screening details |
Total of 180 subjects who previously received etravirine (ETR) in a clinical trial with ETR (EudraCT numbers: 2005-003145-13,2006-001287-23,2006-001287-23,2007-007086-21,2012-002630-36) continued its use, in countries where at time parent clinical trial closed, ETR was not available, could not be accessed through any source were enrolled in study. | ||||||
|
Period 1
|
|||||||
Period 1 title |
Overall Study (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Non-randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
Not blinded
|
||||||
|
Arms
|
|||||||
|
Arm title
|
Etravirine | ||||||
Arm description |
Subjects who previously received etravirine(ETR) in clinical trial with ETR(2005-003145-13, 2006-001287-23, 2006-001287-23, 2007-007086-21, 2012-002630-36) sponsored by/in collaboration with Janssen Research & Development, continued to benefit from its use, in countries where ETR was not available, could not be accessed through another source, or where subject was not eligible for ongoing trials with ETR received ETR 200milligrams (mg) twice daily (bid) in adults. Pediatric subjects received ETR doses as received in previous ETR (parent) trial, with weight based dose adjustment if necessary(ETR 100mg twice daily for weight 10 to less than [<] 20 kilograms [kg]; ETR 125mg bid for weight 20 to <25kg; ETR 150mg bid for weight 25 to <30kg; and 200mg bid for weight greater than or equal to [>=] 30kg). Treatment continued until one of following criteria was met: subject no longer benefited from ETR treatment, toxicity, loss to follow up, ETR became commercially available for subject's use. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Etravirine
|
||||||
Investigational medicinal product code |
|||||||
Other name |
TMC125
|
||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Adult subjects received a dose of ETR 200 mg twice daily. Pediatric subjects received ETR, dosed as they had received in the previous ETR (parent) trial, with weight based dose adjustment if necessary (ETR 100 mg twice daily for weight 10 to less than [<] 20 kilograms [kg]; ETR 125 mg bid for weight 20 to <25 kg; ETR 150 mg bid for weight 25 to <30 kg; and 200 mg bid for weight greater than or equal to [>=] 30 kg).
|
||||||
|
|||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Etravirine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who previously received etravirine(ETR) in clinical trial with ETR(2005-003145-13, 2006-001287-23, 2006-001287-23, 2007-007086-21, 2012-002630-36) sponsored by/in collaboration with Janssen Research & Development, continued to benefit from its use, in countries where ETR was not available, could not be accessed through another source, or where subject was not eligible for ongoing trials with ETR received ETR 200milligrams (mg) twice daily (bid) in adults. Pediatric subjects received ETR doses as received in previous ETR (parent) trial, with weight based dose adjustment if necessary(ETR 100mg twice daily for weight 10 to less than [<] 20 kilograms [kg]; ETR 125mg bid for weight 20 to <25kg; ETR 150mg bid for weight 25 to <30kg; and 200mg bid for weight greater than or equal to [>=] 30kg). Treatment continued until one of following criteria was met: subject no longer benefited from ETR treatment, toxicity, loss to follow up, ETR became commercially available for subject's use. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
|
End points reporting groups
|
|||
Reporting group title |
Etravirine
|
||
Reporting group description |
Subjects who previously received etravirine(ETR) in clinical trial with ETR(2005-003145-13, 2006-001287-23, 2006-001287-23, 2007-007086-21, 2012-002630-36) sponsored by/in collaboration with Janssen Research & Development, continued to benefit from its use, in countries where ETR was not available, could not be accessed through another source, or where subject was not eligible for ongoing trials with ETR received ETR 200milligrams (mg) twice daily (bid) in adults. Pediatric subjects received ETR doses as received in previous ETR (parent) trial, with weight based dose adjustment if necessary(ETR 100mg twice daily for weight 10 to less than [<] 20 kilograms [kg]; ETR 125mg bid for weight 20 to <25kg; ETR 150mg bid for weight 25 to <30kg; and 200mg bid for weight greater than or equal to [>=] 30kg). Treatment continued until one of following criteria was met: subject no longer benefited from ETR treatment, toxicity, loss to follow up, ETR became commercially available for subject's use. | ||
|
|||||||
End point title |
Number of Subjects With at Least One Adverse Event as a Measure of Safety Through the Time Etravirine (ETR)-Based Treatment Regimen Became Commercially Available [1] | ||||||
End point description |
An adverse event is any untoward medical event that occurs in a subject administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Safety analysis set included all subjects who received at least one dose of etravirine.
|
||||||
End point type |
Primary
|
||||||
End point timeframe |
Up to 10 years 11 months
|
||||||
| Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported for this endpoint. |
|||||||
|
|||||||
| No statistical analyses for this end point | |||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 10 years 11 months
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Safety analysis set included all subjects who received at least one dose of etravirine.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
23.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Etravirine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who previously received etravirine(ETR) in a clinical trial with ETR (2005-003145-13, 2006-001287-23, 2006-001287-23, 2007-007086-21, 2012-002630-36) sponsored by/in collaboration with Janssen Research & Development, continued to benefit from its use, in countries where ETR was not available, could not be accessed through another source, or where subject was not eligible for ongoing trials with ETR received ETR 200milligrams (mg) twice daily (bid) in adults. Pediatric subjects received ETR doses as received in previous ETR (parent) trial, with weight based dose adjustment if necessary(ETR 100mg twice daily for weight 10 to less than [<] 20kilograms [kg]; ETR 125mg bid for weight 20 to <25kg; ETR 150mg bid for weight 25 to<30kg; and 200mg bid for weight greater than or equal to [>=] 30kg). Treatment continued until one of following criteria was met: subject no longer benefited from ETR treatment, toxicity, loss to follow up, ETR became commercially available for subject's use. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
Substantial protocol amendments (globally) |
|||
| Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
| Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
| Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
| None reported | |||